Are we repeating mistakes of the past? A review of the evidence for esketamine / Mark A. Horowitz en The British Journal of Psychiatry, Año 2021 - Vol. 219 - No. 5 (Noviembre)

Público ISBD [artículo]  inThe British Journal of Psychiatry > Año 2021 - Vol. 219 - No. 5 (Noviembre) . - pp. 614 - 617 Título : Are we repeating mistakes of the past? A review of the evidence for esketamine Tipo de documento: texto impreso Autores: Mark A. Horowitz, Autor ; Joanna Moncrieff, Autor Fecha de publicación: 2022 Artículo en la página: pp. 614 - 617 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esketamina, Ketamina, Depresión, Antidepresivos, Suicidio Resumen: Esketamine has been licensed for ‘treatment-resistant depression’ in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent. Link: ./index.php?lvl=notice_display&id=28500 [artículo] Are we repeating mistakes of the past? A review of the evidence for esketamine [texto impreso] / Mark A. Horowitz, Autor ; Joanna Moncrieff, Autor . - 2022 . - pp. 614 - 617. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The British Journal of Psychiatry > Año 2021 - Vol. 219 - No. 5 (Noviembre) . - pp. 614 - 617 Palabras clave: Esketamina, Ketamina, Depresión, Antidepresivos, Suicidio Resumen: Esketamine has been licensed for ‘treatment-resistant depression’ in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent. Link: ./index.php?lvl=notice_display&id=28500

---

1 (1 - 1 / 1)